Truist Securities Rates Sutro Biopharma (STRO) buy

Truist Securities has raised its rating on Sutro Biopharma to 'buy' with a target price of $50, a 89.75% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:14 PM EDT · Updated Jun 13, 2026, 1:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Truist Securities rated Sutro Biopharma, Inc. ($STRO) "buy" with a $50 price target on June 11, 2026.

Since the rating, $STRO is up 11.9% after 1 week, up 5.1% after 1 month and down 58.7% to date (from the $26.48 close on Jun 11, 2026).

STRO Sutro Biopharma, Inc.

$10.94 -0.18% year to date

Daily close · Oct 16, 2026

Key Points

On June 11, 2026, Truist Securities upgraded Sutro Biopharma (STRO) to a 'buy' rating with a price target of $50, reflecting a positive outlook for the company's future.
Truist Securities's $50 price target implies 89.75% upside from Sutro Biopharma, Inc.'s ($STRO) current $26.35 share price.
Sutro Biopharma's stock recently closed at $26.35, which is significantly above its 52-week low of $7.15, indicating strong market interest.
Analysts have a consensus 'strong buy' rating for Sutro Biopharma, with an average price target of $47.23 based on 13 opinions.

Get $STRO trade alerts by text

We text you when insiders, Congress or big funds trade $STRO. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Sutro Biopharma, Inc. alert may contain errors. Disclosures

Truist Securities Upgrades Sutro Biopharma's Rating

Truist Securities upgraded Sutro Biopharma, Inc. (STRO) to a 'buy' rating on June 11, 2026, with a price target set at $50. This change signals increased confidence in the company's future prospects in the biotechnology sector, particularly given its focus on innovative cancer treatments.

Understanding the Upgrade

This upgrade reflects a shift in sentiment for Sutro Biopharma. Truist's move to a 'buy' rating comes as the firm sees potential growth from its lead drug candidate, STRO-004, and other therapeutics in development. The recent closing price of $26.35 represents a notable increase from its 52-week low of $7.15, suggesting investors are responding positively to the firm's progress and market positioning.

Institutional Interest in Sutro Biopharma

No other funds have reported changes in their positions regarding Sutro Biopharma in this latest round of filings, indicating a potential lack of immediate competition in terms of institutional interest. This could imply more room for growth or additional attention from institutional investors in the future as the company advances its clinical trials.

Stock Performance and Current Position

Sutro Biopharma's stock currently trades at $26.35, reflecting a significant rise from its 52-week low. The stock's performance suggests that investors are optimistic about the company's developments and the prospects of its ongoing clinical trials. The recent rating upgrade by Truist Securities suggests that market analysts are becoming increasingly bullish on Sutro's future.

12-month forecast

$STRO price target

Sutro Biopharma, Inc. daily closes and this analyst's $50 target. Not advice.

Recent Earnings

Sutro Biopharma reported revenue of $45.7 million, although it faced challenges with revenue growth, which declined by approximately 84.6%. The company's next earnings report is expected on August 11, 2025, providing an opportunity for investors to gain insights into its financial health and operational progress.

Analysts Set New Price Targets

On October 15, 2026, Wedbush reiterated its 'Outperform' rating on Sutro Biopharma with a price target of $60. Additionally, Citizens maintained a 'Market Outperform' rating but adjusted its target from $41 to $34. Analysts remain optimistic about the company's potential, as reflected in the consensus rating of 'strong buy' and an average target price of $47.23 based on 13 opinions.

What STRO Does

Sutro Biopharma operates in the healthcare sector, focusing on developing novel antibody drug conjugates (ADCs) for oncology treatments. Its innovative approach positions it well to address significant medical needs in cancer therapy, particularly with products like STRO-004 and STRO-003.

What to Watch at STRO

Investors will be closely watching Sutro Biopharma as they prepare for the upcoming earnings report in August 2025. The recent upgrade from Truist Securities might lead to increased interest and trading activity in the stock. It's important to consider that the rating reflects the analysts' views as of June 11 and may not represent current market conditions.